Aciphex: Advanced Relief from Acid-Related Gastrointestinal Conditions
| Product dosage: 20mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.94 | $56.23 (0%) | 🛒 Add to cart |
| 90 | $0.87 | $84.35 $78.32 (7%) | 🛒 Add to cart |
| 120 | $0.84 | $112.46 $100.41 (11%) | 🛒 Add to cart |
| 180 | $0.80 | $168.70 $143.59 (15%) | 🛒 Add to cart |
| 270 | $0.78 | $253.04 $209.87 (17%) | 🛒 Add to cart |
| 360 | $0.76
Best per pill | $337.39 $275.14 (18%) | 🛒 Add to cart |
Synonyms | |||
Aciphex (rabeprazole sodium) is a proton pump inhibitor (PPI) designed for the management and treatment of acid-related disorders. Clinically proven to suppress gastric acid secretion, it offers sustained relief and promotes healing of erosive or ulcerative gastroesophageal reflux disease (GERD), duodenal ulcers, and pathological hypersecretory conditions. Its targeted mechanism ensures precise, long-lasting acid control, making it a first-line therapeutic option for gastroenterologists and primary care providers. With a well-established safety profile and predictable pharmacokinetics, Aciphex remains a cornerstone in gastrointestinal pharmacotherapy.
Features
- Active ingredient: Rabeprazole sodium
- Available in delayed-release tablet formulations: 20 mg
- Designed for once-daily oral administration
- Enteric coating to ensure drug stability in acidic environments
- Rapid onset of action with acid suppression within one hour
- Extended duration of effect, maintaining pH >4 for over 18 hours
- Compatible with long-term maintenance therapy
Benefits
- Provides rapid and sustained relief from heartburn, regurgitation, and other GERD symptoms
- Promotes complete healing of erosive esophagitis with high efficacy rates
- Reduces the risk of ulcer recurrence in H. pylori eradication regimens
- Minimizes nocturnal acid breakthrough, improving sleep quality
- Enhances quality of life by allowing normal dietary and lifestyle patterns
- Supports mucosal healing in Zollinger-Ellison syndrome and other hypersecretory states
Common use
Aciphex is indicated for the short-term treatment (4 to 8 weeks) in healing and symptomatic relief of erosive GERD. It is also approved for the maintenance of healed erosive esophagitis and treatment of symptomatic GERD. Additionally, it is used in combination with antibiotics for Helicobacter pylori eradication to reduce the risk of duodenal ulcer recurrence. Off-label uses may include management of NSAID-induced ulcers, Barrett’s esophagus, and functional dyspepsia, under specialist supervision.
Dosage and direction
The recommended adult dosage for healing of erosive GERD is 20 mg once daily for 4 to 8 weeks. For maintenance therapy, 20 mg once daily is advised. For H. pylori eradication, Aciphex 20 mg is taken twice daily alongside amoxicillin and clarithromycin for 7 days. Tablets should be swallowed whole, with or without food, and must not be crushed, split, or chewed. Dosage adjustments are not typically required in elderly patients or those with mild to moderate renal or hepatic impairment, though caution is advised in severe hepatic dysfunction.
Precautions
Patients should be advised that Aciphex may mask symptoms of gastric malignancy; appropriate diagnostic evaluation should be conducted if alarm features (e.g., unintended weight loss, recurrent vomiting, dysphagia) are present. Long-term use may be associated with increased risk of Clostridium difficile-associated diarrhea, hypomagnesemia (especially with prolonged therapy), and vitamin B12 deficiency. Bone fracture risk may be increased with high-dose or long-term PPI therapy. Use during pregnancy only if clearly needed; caution is advised in nursing mothers.
Contraindications
Aciphex is contraindicated in patients with known hypersensitivity to rabeprazole, substituted benzimidazoles, or any component of the formulation. Concomitant use with rilpivirine-containing products is contraindicated due to the potential for decreased antiviral efficacy. It should not be used in patients receiving atazanavir or nelfinavir, as acid suppression may reduce their absorption and efficacy.
Possible side effect
Common adverse reactions (≥2%) include headache, diarrhea, nausea, vomiting, abdominal pain, and pharyngitis. Less frequently, patients may experience flatulence, constipation, dry mouth, dizziness, rash, or elevated liver enzymes. Rare but serious side effects include anaphylaxis, Stevens-Johnson syndrome, acute interstitial nephritis, and hypomagnesemia. Long-term use has been associated with fundic gland polyps, which are usually benign and reversible upon discontinuation.
Drug interaction
Aciphex may alter the absorption of drugs dependent on gastric pH for bioavailability, such as ketoconazole, iron salts, and digoxin. It can increase systemic concentrations of methotrexate. Concomitant use with warfarin may require monitoring of INR due to potential increases in bleeding risk. As a weak CYP2C19 inhibitor, rabeprazole may interact with drugs metabolized by this enzyme, such as phenytoin or diazepam. Avoid coadministration with clopidogrel due to potential reduction in antiplatelet activity.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. In that case, the missed dose should be skipped, and the regular dosing schedule resumed. Doubling the dose is not recommended.
Overdose
Limited data exist on Aciphex overdose. Reported doses of up to 80 mg daily have been tolerated. Symptoms may reflect exaggerated pharmacologic effects (e.g., hypochlorhydria) or include drowsiness, blurred vision, tachycardia, and nausea. Management is supportive; dialysis is not likely to be effective due to high protein binding. Gastric lavage may be considered if ingestion is recent.
Storage
Store at controlled room temperature, 20–25°C (68–77°F), in a dry place. Protect from light and moisture. Keep in the original container with the lid tightly closed. Do not use if the blister pack or bottle seal is broken. Keep out of reach of children and pets.
Disclaimer
This information is intended for educational purposes and does not replace professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting or changing any medication regimen. Individual patient responses may vary.
Reviews
Clinical studies demonstrate healing rates of 85–93% for erosive esophagitis after 8 weeks of Aciphex therapy. Patient-reported outcomes indicate significant improvement in GERD-related quality of life scores. In comparative trials, Aciphex showed non-inferiority to other PPIs in symptom resolution and healing efficacy. Long-term maintenance studies confirm sustained remission in most patients with once-daily dosing. Real-world evidence supports its tolerability and effectiveness in diverse patient populations.